PURPOSE: The objective of this study was to demonstrate the safety and performance of a unique extracorporeal carbon dioxide removal system (Hemolung, ALung Technologies, Pittsburgh, PA) which incorporates active mixing to improve gas exchange efficiency, reduce exposure of blood to the circuit, and provide partial respiratory support at dialysis-like settings. METHODS: An animal study was conducted using eight domestic crossbred sheep, 6-18 months of age and 49-115 kg in weight. The sheep were sedated and intubated, and a 15.5-Fr dual lumen catheter was inserted into the right jugular vein. The catheter was connected to the extracorporeal circuit primed with heparinized saline, and flow immediately initiated. The animals were then awakened and encouraged to stand. The animals were supported in a stanchion and monitored around the clock. Anticoagulation was maintained with heparin to achieve an aPTT of 46-70 s. RESULTS: Measurements included blood flow rate through the device, carbon dioxide exchange rate, pump speed and sweep gas flow rate. Safety and biocompatibility measurements included but were not limited to plasma-free hemoglobin, hematocrit, white blood cell count, platelet count and fibrinogen. The Hemolung removed clinically significant amounts of carbon dioxide, more than 50 ml/min, at low blood flows of 350-450 ml/min, with minimal adverse effects. CONCLUSIONS: The results of 8-day trials in awake and standing sheep supported by the Hemolung demonstrated that this device can consistently achieve clinically relevant levels of carbon dioxide removal without failure and without significant risk of adverse reactions.
PURPOSE: The objective of this study was to demonstrate the safety and performance of a unique extracorporeal carbon dioxide removal system (Hemolung, ALung Technologies, Pittsburgh, PA) which incorporates active mixing to improve gas exchange efficiency, reduce exposure of blood to the circuit, and provide partial respiratory support at dialysis-like settings. METHODS: An animal study was conducted using eight domestic crossbred sheep, 6-18 months of age and 49-115 kg in weight. The sheep were sedated and intubated, and a 15.5-Fr dual lumen catheter was inserted into the right jugular vein. The catheter was connected to the extracorporeal circuit primed with heparinized saline, and flow immediately initiated. The animals were then awakened and encouraged to stand. The animals were supported in a stanchion and monitored around the clock. Anticoagulation was maintained with heparin to achieve an aPTT of 46-70 s. RESULTS: Measurements included blood flow rate through the device, carbon dioxide exchange rate, pump speed and sweep gas flow rate. Safety and biocompatibility measurements included but were not limited to plasma-free hemoglobin, hematocrit, white blood cell count, platelet count and fibrinogen. The Hemolung removed clinically significant amounts of carbon dioxide, more than 50 ml/min, at low blood flows of 350-450 ml/min, with minimal adverse effects. CONCLUSIONS: The results of 8-day trials in awake and standing sheep supported by the Hemolung demonstrated that this device can consistently achieve clinically relevant levels of carbon dioxide removal without failure and without significant risk of adverse reactions.
Authors: S Nava; F Rubini; E Zanotti; N Ambrosino; C Bruschi; M Vitacca; C Fracchia; C Rampulla Journal: Eur Respir J Date: 1994-09 Impact factor: 16.671
Authors: J D Kimmel; D T Arazawa; S-H Ye; V Shankarraman; W R Wagner; W J Federspiel Journal: J Mater Sci Mater Med Date: 2013-07-26 Impact factor: 3.896
Authors: Alexander Hermann; Katharina Riss; Peter Schellongowski; Andja Bojic; Philipp Wohlfarth; Oliver Robak; Wolfgang R Sperr; Thomas Staudinger Journal: Intensive Care Med Date: 2015-07-14 Impact factor: 17.440
Authors: R Garrett Jeffries; Yerbol Mussin; Denis S Bulanin; Laura W Lund; Ergin Kocyildirim; Zhaksybay Zh Zhumadilov; Farkhad S Olzhayev; William J Federspiel; Peter D Wearden Journal: Int J Artif Organs Date: 2014-12-13 Impact factor: 1.595